Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of hematologic malignancy characterized by lesions in subcutaneous fat associated with systemic symptoms. The standard treatment of the disease, currently, is not established, but CHOP or CHOP-like regimens are usually given. We r...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2007-01, Vol.48 (3), p.560-563
Main Authors: Rojnuckarin, Ponlapat, Nakorn, Thanyaphong Na, Assanasen, Thamathorn, Wannakrairot, Pongsak, Intragumtornchai, Tanin
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - therapeutic use
Cyclophosphamide - therapeutic use
cyclosporin
Cyclosporine - therapeutic use
Cytarabine - therapeutic use
Doxorubicin - therapeutic use
Etoposide - therapeutic use
Female
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
Humans
Immunosuppressive Agents - therapeutic use
Lymphoma, T-Cell, Cutaneous - drug therapy
Male
Methylprednisolone - therapeutic use
Middle Aged
panniculitis
Panniculitis - pathology
Prednisone - therapeutic use
Prognosis
Remission Induction
Skin Neoplasms - drug therapy
T-cell lymphoma
Treatment Outcome
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of hematologic malignancy characterized by lesions in subcutaneous fat associated with systemic symptoms. The standard treatment of the disease, currently, is not established, but CHOP or CHOP-like regimens are usually given. We report, herein, 4 cases of SPTCL diagnosed by histopathology and immunohistochemistry who were refractory to CHOP and or ESHAP and or fludarabine-based regimen, but showed rapid improvement within weeks after oral cyclosporin 4 mg kg day. Three sustained complete remission for the durations of 8 - 9 months off-treatments. T-cell receptor gene rearrangement revealed polyclonality in 3 cases and monoclonality in 1 case. Our data suggest the benefit of incorporating cyclosporin into the treatment regimen for SPTCL.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190601078456